Identifying treatment weaknesses in acute myeloid leukemia (AML) through studying a specific gene's role.
Official title: Uncovering therapeutic vulnerabilities in AML through mechanistic interrogation of MECOM activity
Funded at Ut Southwestern Medical Center · NIH-11248254 · Data updated 2026-11-12
This study is looking at a protein called MECOM to understand how it affects acute myeloid leukemia (AML) and hopes to find new ways to treat patients by discovering important genes that help keep the leukemia going.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $228,979 |
| NIH project number | 7K08CA286756-02 |
| Project ID | NIH-11248254 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who may benefit from novel therapeutic strategies.
✕Less likely to help
Patients with other types of leukemia or those who do not have AML may not receive any benefit from this research.
What this research studies
This research investigates the role of the MECOM transcription factor in acute myeloid leukemia (AML) to uncover new treatment strategies. By examining how MECOM regulates gene expression and interacts with other cellular pathways, the study aims to identify critical genes that contribute to the maintenance of AML. The approach involves detailed mechanistic studies to pinpoint essential co-regulators and downstream effectors of MECOM, which could lead to targeted therapies for patients with AML.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve treatment outcomes for patients with AML.
How similar studies have gone: Other research has shown promise in targeting specific gene pathways in leukemia, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Voit, Richard a — Ut Southwestern Medical Center
- Study coordinator: Voit, Richard a
Related research
Other NIH-funded projects on the same topics.
-
Developing targeted therapies for Ewing sarcoma
This study is working on new treatments for Ewing sarcoma, a cancer that mainly affects kids and teens, by finding ways to target a specific protein that helps the cancer grow, so that we can offer safer and better options for those fighting this disease.
-
Neural roots of how autistic adults understand word meaning
A study to understand how adults with autism process word meanings in the brain, aiming to improve language support.
-
A new approach to healing NF1-related tibia fractures in children
This grant aims to understand why some NF1-related leg fractures in kids don’t heal well and to develop better treatments to help them recover without complications.
-
Multi-center study on how ventilation during CPR relates to cardiac arrest outcomes
A large, real-world study will look at how ventilation during CPR affects survival after out-of-hospital cardiac arrest in adults.
-
National Spina Bifida Patient Registry across the U.S.
A national registry collects health information from people with spina bifida to help doctors and families get better, more consistent care.
-
MONA-LISA: Understanding Why Autoimmune Signals Turn into Lupus Over Time
A study using data and samples from people with early autoimmune signs to understand why some develop full-blown lupus and others do not.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.